Last reviewed · How we verify
NCT03050788
Smartphone Confocal Microscopy for Diagnosing Kaposi's Sarcoma
NA trial testing Smartphone confocal microscopy in Kaposi Sarcoma in 363 participants. Completed in 28 February 2020.
28 February 2020
Quick facts
| Lead sponsor | Massachusetts General Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 363 |
| Start date | 10 March 2017 |
| Primary completion | 28 February 2020 |
| Estimated completion | 28 February 2020 |
| Sites | 1 location across Uganda |
Drugs / interventions tested
- Smartphone confocal microscopy
Conditions studied
- Kaposi Sarcoma — all drugs for Kaposi Sarcoma →
Sponsor
Massachusetts General Hospital
Who can join
18 and older, any sex, with Kaposi Sarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators propose to evaluate a novel diagnostic approach for Kaposi's sarcoma (KS) that may be eventually deployed with portable, point-of-care techniques. This approach features confocal microscopy. The investigators will compare this new approach with the gold standard of histology from a traditional skin punch biopsy (which is standard of care) to determine the sensitivity and specificity of portable confocal microscopy in diagnosing KS.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03050788
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kaposi Sarcoma
Currently open trials in the same condition.
- NCT07308886 — Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and I · Phase 2 · recruiting
- NCT06445166 — Propranolol for the Treatment of Kaposi Sarcoma in Adults · Phase 2 · recruiting
- NCT06751355 — Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): A Device Feasibility Trial · recruiting
- NCT06375122 — Natural History Study of Kaposi Sarcoma · recruiting
- NCT06004011 — AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW) · NA · recruiting
Other Massachusetts General Hospital trials
Trials by the same sponsor.
- NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
- NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
- NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
- NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
- NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03050788 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
- Last refreshed: 26 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03050788.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing